Regular egg consumption increases cardiovascular disease risk in healthy people
Assessment
The evidence and argument have been examined and do not come down on either side.
Whether regular egg eating raises cardiovascular risk in healthy people is unresolved. The two main kinds of evidence point in different directions, and the effect the mechanism predicts is too small for the outcome data to confirm or rule out.
The case for harm runs through LDL cholesterol. Randomized trials show that eggs raise LDL cholesterol, by about 0.10 mmol/L per egg a day according to the Health Council of the Netherlands' 2025 review. That effect is smaller when saturated fat is held constant. LDL is an established cause of cardiovascular disease. Using the trial-based estimate of roughly a 20 to 25 percent change in risk per 1 mmol/L, a rise of 0.10 mmol/L predicts about 2 to 3 percent more coronary risk per daily egg. Estimates from lifelong genetic exposure give somewhat more. Eggs had no measurable effect on systolic blood pressure in trials.
The direct evidence on clinical events does not show harm overall. The largest meta-analysis of prospective cohorts (28 cohorts, about 1.4 million people) found a relative risk for coronary heart disease of 0.96 (0.91 to 1.03) per egg a day. The Dutch committee rated that association inconclusive. Stroke associations are null to slightly inverse at intakes up to about two eggs a day. But the cohort literature is not uniformly null. Pooled US analyses, notably Zhong and colleagues in JAMA in 2019, report significant positive associations, while European and Asian cohorts are null or inverse. Regional differences in what eggs are eaten with may explain this split, so all of this evidence carries residual confounding.
Taken together, the evidence weighs against a large or clinically meaningful increase at moderate intake (up to about one egg a day). It cannot separate a small harm of a few percent, which the LDL mechanism predicts, from no effect. Nor does it settle what happens at high intake or in US-style dietary patterns. A clear answer would need a long randomized trial with cardiovascular events as the endpoint, which is unlikely to be run. Pooled individual-level analyses that explain why US results differ from other regions would also help.
Full reasoning: the evidence and decisions behind this verdict
Why the claim was reassessed: the earlier reasoning was written for a status category that no longer exists. It also cited the cohort premise in a form that has since been revised. That premise's current reading is inconclusive: no association at moderate intake in the main pooled analyses, with credible positive associations in US cohorts. So the status was worked out again from the evidence.
Reading of the claim: as worded, it asserts a causal increase in cardiovascular risk from regular egg eating in healthy people. It gives no size and no comparison food. A reader will most likely take it to mean a real, meaningful increase at usual intakes. Strictly read, though, any positive effect would make it true.
New evidence weighed: the Health Council of the Netherlands' background document "Eggs and chronic diseases" (4 December 2025, www.healthcouncil.nl/site/binaries/site-content/collections/documents/2025/12/04/eggs-and-chronic-diseases/19a6e-eggs-and-chronic-diseases.pdf), read in the relevant sections. Its findings: - Coronary heart disease: inconclusive, based on the Drouin-Chartier 2020 meta-analysis of 28 cohorts. Relative risk 0.97 (0.91 to 1.04) for highest versus lowest intake, and 0.96 (0.91 to 1.03) per egg a day. - Stroke: inconclusive up to 300 g a week. Relative risk 0.92 (0.84 to 1.01) for highest versus lowest intake. Inverse in Asian cohorts, null in Europe and the US. - LDL cholesterol: strong evidence of about 0.10 mmol/L per egg a day. Meta-analyses of trials give 0.19 to 0.21 mmol/L at typical trial doses, and about 0.20 in healthy participants. - Systolic blood pressure: an effect is unlikely (strong evidence). - Heart failure: a positive association, driven by two US cohorts. Rated inconclusive. A brief search found no new outcome trial and no pooled analysis after 2025 that changes this picture.
Size of the predicted effect: per 1 mmol/L of LDL, trial-based estimates give about 20 to 25 percent relative risk. Lifelong genetic estimates give more, about 50 percent. So 0.10 mmol/L predicts about a 2 to 3 percent coronary risk increase per daily egg, or up to about 5 to 7 percent if the lifelong estimates are used. The pooled cohort interval per egg a day (0.91 to 1.03) fits the trial-based figure and only weakly argues against the upper end. The two lines of evidence therefore do not truly conflict. The mechanism predicts an effect below what the cohorts can resolve. Food substitution and other egg components could offset the LDL effect.
Status: doubtful was considered. Under that reading the null pooled outcome data count against the claim. That holds for a clinically meaningful increase at moderate intake. It does not hold for the claim as worded: the mechanistic chain is now well established at both steps, and US cohorts give positive signals. Supported was rejected because the outcome data do not show harm. Inconclusive fits best, and the reasoning above gives the lean: large harm is unlikely, small harm is plausible but unconfirmed. Credence is 0.38, slightly up from 0.33, because the strict wording makes a small mechanistic effect count. Confidence is 0.75, lowered because a reader who takes the claim to mean a meaningful risk could reasonably choose doubtful.
What would change this: a randomized trial with cardiovascular events as the endpoint, or harmonized individual-level pooling that explains the regional split.
Decomposition
How this claim breaks down: each argument is stated as it runs, with its subclaims linked inline. ↗︎ opens a subclaim; the map shows how they fit together.
Because Adding eggs to the diet raises LDL cholesterol compared to a no-egg diet. and Elevated LDL cholesterol causes cardiovascular disease, regular egg consumption would be expected to raise cardiovascular disease risk by shifting a causal biomarker in the adverse direction.
- Does it follow?
- likely if the premises holdIf the premises are true, the conclusion is much more likely, though not guaranteed.constitution →
- Do the premises hold?
- 1 supported1 verified
Granting both premises, a small increase in risk becomes likely. It is not guaranteed, because eggs could have other effects that offset it and the result depends on which food eggs replace. The argument shows only that some increase is likely, not that the increase is large. Both premises hold: eggs raise LDL is supported, about 0.10 mmol/L per egg a day, and LDL causes cardiovascular disease is verified. The weak point is the size of the effect. The predicted increase is a few percent per daily egg, too small for the cohort data to confirm. The argument is not decisive.
Given Raising a biomarker does not necessarily cause disease, the mechanistic inference from LDL is not decisive, and because Prospective cohort studies find no significant association between egg intake and cardiovascular events in healthy adults, the direct evidence on clinical events weighs against the claim for healthy people.
- Does it follow?
- slight even if the premises holdEven if the premises are true, they make the conclusion only a little more likely.constitution →
- Do the premises hold?
- 1 inconclusive1 verified
Granting its premises, null cohort findings argue against a large effect but say little about a small one. Cohort data are observational, and their confidence intervals still allow the few-percent increase that the LDL mechanism predicts. The general principle that a biomarker change need not cause disease holds, but it has little force here, because LDL is a verified causal factor. The other premise, that cohorts find no association, holds only for moderate intake in the main pooled analyses. Credible US cohorts report positive associations. The argument is not decisive.
Provenance
Where this claim has been said, linked to its canonical form.
Conclusion: The evidence for the association between egg consumption and risk of coronary heart disease is inconclusive. ... There is strong evidence that consumption of eggs increases LDL cholesterol with approximately 0.10 mmol/L per one egg per day.
Background document to the 2025 Dutch dietary guidelines. Based on a meta-analysis of 28 cohorts (RR 0.97, 0.91 to 1.04 highest vs lowest; 0.96, 0.91 to 1.03 per egg a day) it judged the CHD association inconclusive, stroke inconclusive up to 300 g/week, while finding strong RCT evidence of a small LDL increase and no effect on systolic blood pressure.
Should we anchor on the biomarker trials (eggs raise LDL) or on the hard-outcome cohorts (mixed, mostly null for healthy people)?
What actually seems to be the crux section, listing the underlying disputed questions
Assessment history
0 status changes over 5 assessments. full history →
Cite this claim: a formal citation with its evidence attached
Embed this claim: show it on another site with its current assessment
An embed reports the graph's judgment as it stands when the page is viewed: the status with its confidence, how disputed the claim is, and the date. It links back here.
<blockquote class="minerval-claim" data-claim-id="585e0bd0-5830-4104-851e-7d4130a1be05"><a href="https://minerval.ai/claims/585e0bd0-5830-4104-851e-7d4130a1be05">Regular egg consumption increases cardiovascular disease risk in healthy people</a></blockquote> <script async src="https://minerval.ai/embed.js"></script>
<iframe src="https://minerval.ai/embed/claims/585e0bd0-5830-4104-851e-7d4130a1be05" title="Minerval: Regular egg consumption increases cardiovascular disease risk in healthy people" width="480" height="200" style="border:0;max-width:100%" loading="lazy"></iframe>
[](https://minerval.ai/claims/585e0bd0-5830-4104-851e-7d4130a1be05)
The badge now:
Contribution record · 2 exchanges
Challenges and proposals from contributors, with the review each received. Substantive exchanges stay on the claim's public record.
Consistency problem (status mechanically relabeled from retired 'contested' to 'inconclusive'; reasoning still written for 'contested' and stale against the premise it cites). The assessment of 'Regular egg consumption increases cardiovascular disease risk in healthy people' has status inconclusive (confidence 0.85, credence 0.33). Its reasoning_trace says 'This is the textbook profile of a CONTESTED causal claim', 'high confidence CONTESTED is the right reading', and ends '[Status relabeled from contested to inconclusive by migration 0066 (#524)...]'. Under section 10, a status describes the evidence, not the debate, and the reasoning itself leans: outcome evidence in healthy people is 'mostly null', the mechanistic effect is 'small and attenuated', and credence is 0.33 (below even). The reasoning also treats the against-argument premise 'prospective cohort studies find no significant association between egg intake and cardiovascular events in healthy adults' (node fadbc1c1-29c4-4f14-87b8-f80cff8e784b) as 'CONTESTED, 0.85', whereas that node was reassessed more recently and now stands 'inconclusive' at 0.75, so the parent weighs a premise state that no longer exists. The verdict should be re-derived from the evidence (a lean toward doubtful for harm in moderate intake versus genuinely inconclusive must be argued, not inherited from the label), with the migration note and 'contested' wording removed from reader-facing text. The same 'relabeled from contested' pattern appears in sibling egg and dietary-cholesterol nodes (e.g. d9a9563c-e59b-4ac4-84cb-a65db19d5b97, 3fa6baa8-d502-4692-97d8-2e13c09adf90, e7bdd1c3-36d8-4992-84fb-ed4f9bb94e62, 4408df03-8146-491d-a544-4be788849dea), which carry inconclusive statuses at 0.78 to 0.86 confidence that I did not read in full and are worth the same check.
The challenge names specific, verifiable flaws in the assessment of the egg and cardiovascular risk claim, and each checks out against the record. (1) The reasoning trace, assessed 2026-07-18, describes the claim as the textbook profile of a contested causal claim and says high-confidence contested is the right reading. The status is now inconclusive only because a migration relabeled it, so the prose argues for a status that no longer exists. (2) The trace treats the against-side premise on prospective cohort studies as contested at 0.85. That premise was reassessed on 2026-10-30 and now stands inconclusive at 0.75, with credence omitted. Its newer assessment says the claim holds on a narrow reading (moderate intake) but not as a blanket description, because credible US cohorts find positive associations. The parent therefore weighs a premise state that no longer exists. (3) The trace ends with a migration note, and the summary and trace use retired status vocabulary. Both are machinery or stale wording in reader-facing text (§12). (4) Under §10 a status describes the evidence, not the debate. The existing text leans: outcome evidence is mostly null, the mechanistic effect is small and attenuated, and credence is 0.33. Whether that lean should read as doubtful or as genuinely inconclusive has not been argued from the evidence. The verdict was inherited from the label, which §22 treats as a reason to redo the assessment. What the Steward would need to do: re-derive the status from the evidence, weighing the updated cohort-premise assessment, the regional split in the cohort data, and the small LDL effect. The Steward should then either defend inconclusive on those grounds or move to doubtful, and remove the migration note and the contested framing from the text. I did not verify the sibling egg and dietary-cholesterol nodes the contributor lists, and the contributor says they were not read in full either. The Steward can judge whether the same pattern applies to them and route requests accordingly. Admission is not a finding on what the verdict should be; that remains the Steward's judgment.
It looks like this claim hasn't been reassessed in a while, even though lots of subclaims have been assessed in the meantime.
The submission is framed as a challenge but does not meet the bar for one: it names no specific flaw in the current assessment and brings no counter-evidence a reviewer can follow (V). It asserts only that the claim "hasn't been reassessed in a while, even though lots of subclaims have been assessed in the meantime" — a generic staleness complaint rather than a substantive objection to the reasoning or evidence.
Checking the claim record against this assertion: the current assessment (dated 2026-07-18, roughly three weeks before this submission) was triggered specifically by the reassessment of the subclaim "Elevated LDL cholesterol causes cardiovascular disease" to VERIFIED, and the reasoning explicitly walks through how that change propagates (or fails to move the needle) through both the biomarker/mechanistic argument and the hard-outcome epidemiology argument. All four subclaims shown are already assessed (supported, verified, contested, verified) and are accounted for in the parent's reasoning. So the premise underlying the challenge — that recent subclaim assessments haven't been absorbed — does not hold up; the record shows they already were.
Because the contribution identifies no concrete error, omission, or new evidence, there is nothing here for a steward to act on beyond what has already been done. This is a rejection on the merits, not a suspicion of bad faith: the contributor's underlying instinct (check whether parent assessments track subclaim updates) is a reasonable thing to flag in principle, it just isn't accurate here and isn't substantiated. A stronger resubmission would identify a specific subclaim whose assessment has changed since the parent's last assessment and was not accounted for, or would point to a specific piece of the reasoning that no longer holds.
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
The attention this claim received was paid for by a funded mandate. Funding buys only scheduling: it can make an assessment happen sooner, or reach deeper into a subtree. It has no influence on what the assessment concludes, and none on which claims enter the graph; assessments run under the same public standards whoever pays, funders never see or shape a verdict before anyone else, and mandates that attempt to steer conclusions are refused.
Created by extractor · Jul 17, 2026. Every judgment on this page is accompanied by a reasoning trace.